Definium Therapeutics, Inc. SEDAR Filings

News 2026-06-30

Material change report - English.pdf

Transactions 2026-06-25 Financing

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

News release - English.pdf

Transactions 2026-06-24 Financing

Open PDF

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

News release - English.pdf

Transactions 2026-06-24 Financing

Open PDF

Definium Therapeutics, Inc. Announces Proposed Public Offering

News release - English.pdf

Results 2026-06-24

Open PDF

Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026

News release - English.pdf

News 2026-06-22

Open PDF

Definium Therapeutics, Inc. Announced Positive Topline Data from Phase 3 Emerge Study of DT120 ODT for Treatment of Major Depressive Disorder

Material change report - English.pdf

Results 2026-06-22

Open PDF

Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder

News release - English.pdf

News 2026-05-12

Open PDF

Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder

News release - English.pdf

Results 2026-05-07

Open PDF

Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

News release - English.pdf

Results 2026-05-07

Open PDF

Interim MD&A - English.pdf

Results 2026-05-07

Open PDF

Interim financial statements/report – English.pdf

News 2026-04-27

Open PDF

Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day

News release - English.pdf

News 2026-04-27

Open PDF

Definium Therapeutics Applauds White House Executive Order to Accelerate Mental Health Innovation and Expand Access to Psychedelic Medical Treatments

News release - English.pdf

News 2026-04-16

Open PDF

Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

News release - English.pdf

Results 2026-04-16

Open PDF

New Definium Therapeutics Study Published in the Journal of Mood and Anxiety Disorders Reveals Increasing Prevalence and Burden of Generalized Anxiety Disorder in the United States

News release - English.pdf

Results 2026-04-16

Open PDF

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

News release - English.pdf

Results 2026-02-27 Financials

Annual report on form 10-K - English.pdf

Results 2026-02-27 Financials

Open PDF

Annual MD&A - English.pdf

Results 2026-02-27 Financials

Open PDF

Audited annual financial statements – English.pdf

News 2026-02-27

Other.pdf

Results 2026-02-27

Open PDF

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates

News release - English.pdf

News 2026-01-29

Other.pdf

News 2026-01-20

Open PDF

Definium Therapeutics Introduces Rerouting Minds, an Educational Campaign Exploring the Potential of Pharmaceutical Lysergide (LSD) in Mental Health Care

News release - English.pdf

News 2026-01-12